Fig. 2From: Erenumab in highly therapy-refractory migraine patients: First German real-world evidenceDistinct treatment responses regarding migraine characteristics. Patient reported subjective treatment response after three months of erenumab therapy. Migraine-associated vegetative symptoms, dizziness, need for rest and effects of acute medications stayed unaffected in the majority of patient, while duration and intensity of migraine improvedBack to article page